首页> Japanese journal of clinical oncology> Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.

Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.

导出原文传递

翻译打印收藏纠错

第一作者： Hironobu,Hashimoto

第一单位： Department of Pharmacy, National Cancer Center Hospital.

作者： Hironobu,Hashimoto ^[1] ; Masakazu,Abe ^[2] ; Takako,Yanai ^[1] ; Takuhiro,Yamaguchi ^[3] ; Sadamoto,Zenda ^[4] ; Yosuke,Uchitomi ^[5] ; Haruhiko,Fukuda ^[6] ; Mikio,Mori ^[6] ; Satoru,Iwasa ^[7] ; Noboru,Yamamoto ^[8] ; Yuichiro,Ohe ^[9]

作者单位： Department of Pharmacy, National Cancer Center Hospital. ^[1] Department of Gynecologic Oncology, Shizuoka Cancer Center. ^[2] Department of Biostatistics, Tohoku University Graduate School of Medicine. ^[3] Department of Radiation Oncology, National Cancer Center Hospital East.;Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital.;Japan Supportive, Palliative and Psychosocial Oncology Group: J-SUPPORT. ^[4] Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital.;Japan Supportive, Palliative and Psychosocial Oncology Group: J-SUPPORT. ^[5] Data Management Section, National Cancer Center Hospital. ^[6] Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital. ^[7] Department of Experimental Therapeutics, National Cancer Center Hospital. ^[8] Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. ^[9]